These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 36765790)
21. Prognostic and Therapeutic Significance of Circulating Tumor Cell Phenotype Detection Based on Epithelial-Mesenchymal Transition Markers in Early and Midstage Colorectal Cancer First-Line Chemotherapy. Lu G; Lu Z; Li C; Huang X; Luo Q Comput Math Methods Med; 2021; 2021():2294562. PubMed ID: 34777560 [TBL] [Abstract][Full Text] [Related]
22. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Mathiesen RR; Borgen E; Renolen A; Løkkevik E; Nesland JM; Anker G; Ostenstad B; Lundgren S; Risberg T; Mjaaland I; Kvalheim G; Lønning PE; Naume B Breast Cancer Res; 2012 Aug; 14(4):R117. PubMed ID: 22889108 [TBL] [Abstract][Full Text] [Related]
23. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort. Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845 [TBL] [Abstract][Full Text] [Related]
24. Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). Papadaki MA; Messaritakis I; Fiste O; Souglakos J; Politaki E; Kotsakis A; Georgoulias V; Mavroudis D; Agelaki S Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477700 [TBL] [Abstract][Full Text] [Related]
25. Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer. Wang C; Zhang Z; Chong W; Luo R; Myers RE; Gu J; Lin J; Wei Q; Li B; Rebbeck TR; Lu-Yao G; Kelly WK; Yang H Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33450815 [TBL] [Abstract][Full Text] [Related]
26. An exploratory study on the checkout rate of circulating tumor cells and the prediction of efficacy of neoadjuvant therapy and prognosis in patients with HER-2-positive early breast cancer. Zhou J; Wu J; Hao X; Li P; Zhang H; Wu X; Chen J; Liu J; Xiao J; Zhang S; Jiang Z; Yang Y; Hu Z; Wang T Front Oncol; 2022; 12():966624. PubMed ID: 35992876 [TBL] [Abstract][Full Text] [Related]
27. Circulating Tumor Cells Undergoing EMT Provide a Metric for Diagnosis and Prognosis of Patients with Hepatocellular Carcinoma. Qi LN; Xiang BD; Wu FX; Ye JZ; Zhong JH; Wang YY; Chen YY; Chen ZS; Ma L; Chen J; Gong WF; Han ZG; Lu Y; Shang JJ; Li LQ Cancer Res; 2018 Aug; 78(16):4731-4744. PubMed ID: 29915159 [TBL] [Abstract][Full Text] [Related]
28. Detection of circulating tumor cells for prediction of recurrence after adjuvant chemoradiation in locally advanced squamous cell carcinoma of the head and neck. Tinhofer I; Konschak R; Stromberger C; Raguse JD; Dreyer JH; Jöhrens K; Keilholz U; Budach V Ann Oncol; 2014 Oct; 25(10):2042-2047. PubMed ID: 25057171 [TBL] [Abstract][Full Text] [Related]
29. Mesenchymal circulating tumor cells and Ki67: their mutual correlation and prognostic implications in hepatocellular carcinoma. Yang X; Ni H; Lu Z; Zhang J; Zhang Q; Ning S; Qi L; Xiang B BMC Cancer; 2023 Jan; 23(1):10. PubMed ID: 36600214 [TBL] [Abstract][Full Text] [Related]
30. Analysis of a Real-World Cohort of Metastatic Breast Cancer Patients Shows Circulating Tumor Cell Clusters (CTC-clusters) as Predictors of Patient Outcomes. Costa C; Muinelo-Romay L; Cebey-López V; Pereira-Veiga T; Martínez-Pena I; Abreu M; Abalo A; Lago-Lestón RM; Abuín C; Palacios P; Cueva J; Piñeiro R; López-López R Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32365530 [TBL] [Abstract][Full Text] [Related]
31. Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection. Zhou Y; Wang B; Wu J; Zhang C; Zhou Y; Yang X; Zhou J; Guo W; Fan J BMC Cancer; 2016 Jul; 16():506. PubMed ID: 27439521 [TBL] [Abstract][Full Text] [Related]
32. Clinical Significance of Mesenchymal Circulating Tumor Cells in Patients With Oligometastatic Hormone-Sensitive Prostate Cancer Who Underwent Cytoreductive Radical Prostatectomy. Yang G; Xie J; Zhang S; Gu W; Yuan J; Wang R; Guo C; Ye L; Peng B; Yao X; Yang B Front Oncol; 2021; 11():812549. PubMed ID: 35127528 [TBL] [Abstract][Full Text] [Related]
33. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy. Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335 [TBL] [Abstract][Full Text] [Related]
34. Association of circulating tumor cell-white blood cell clusters with survival outcomes in patients with colorectal cancer after curative intent surgery. Xu Y; Zhang Q; Xu Z; Xie Q; Ding W; Liu H; Deng H BMC Gastroenterol; 2022 Dec; 22(1):503. PubMed ID: 36474175 [TBL] [Abstract][Full Text] [Related]
35. Establishment of an optimized CTC detection model consisting of EpCAM, MUC1 and WT1 in epithelial ovarian cancer and its correlation with clinical characteristics. Wang T; Gao Y; Wang X; Tian J; Li Y; Yu B; Huang C; Li H; Liang H; Irwin DM; Tan H; Guo H Chin J Cancer Res; 2022 Apr; 34(2):95-108. PubMed ID: 35685992 [TBL] [Abstract][Full Text] [Related]
36. High-Throughput Label-Free Isolation of Heterogeneous Circulating Tumor Cells and CTC Clusters from Non-Small-Cell Lung Cancer Patients. Zeinali M; Lee M; Nadhan A; Mathur A; Hedman C; Lin E; Harouaka R; Wicha MS; Zhao L; Palanisamy N; Hafner M; Reddy R; Kalemkerian GP; Schneider BJ; Hassan KA; Ramnath N; Nagrath S Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31947893 [TBL] [Abstract][Full Text] [Related]
37. A lab-on-a-disc platform enables serial monitoring of individual CTCs associated with tumor progression during EGFR-targeted therapy for patients with NSCLC. Lim M; Park J; Lowe AC; Jeong HO; Lee S; Park HC; Lee K; Kim GH; Kim MH; Cho YK Theranostics; 2020; 10(12):5181-5194. PubMed ID: 32373206 [No Abstract] [Full Text] [Related]
38. Detection of Circulating Tumor Cells by Fluorescent Immunohistochemistry in Patients with Esophageal Squamous Cell Carcinoma: Potential Clinical Applications. Li SP; Guan QL; Zhao D; Pei GJ; Su HX; Du LN; He JX; Liu ZC Med Sci Monit; 2016 May; 22():1654-62. PubMed ID: 27184872 [TBL] [Abstract][Full Text] [Related]
39. A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma. Court CM; Hou S; Winograd P; Segel NH; Li QW; Zhu Y; Sadeghi S; Finn RS; Ganapathy E; Song M; French SW; Naini BV; Sho S; Kaldas FM; Busuttil RW; Tomlinson JS; Tseng HR; Agopian VG Liver Transpl; 2018 Jul; 24(7):946-960. PubMed ID: 29624843 [TBL] [Abstract][Full Text] [Related]
40. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells. Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]